Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Glatiramer acetate
Drug ID BADD_D01021
Description Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis.
Indications and Usage For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.
Marketing Status approved; investigational
ATC Code L03AX13
DrugBank ID DB05259
KEGG ID D04318
MeSH ID D000068717
PubChem ID 3081884
TTD Drug ID D04CRL
NDC Product Code 0781-3234; 63629-8815; 0441-3642; 14403-0008; 68546-325; 59651-517; 68546-317; 0781-3250; 55111-945; 0378-6960; 53104-7715; 65129-1181; 63850-4035; 63629-8816; 65727-038
UNII 5M691HL4BO
Synonyms Glatiramer Acetate | Acetate, Glatiramer | Copaxone | Glatiramer | TV 5010 | 5010, TV | TV5010 | TV-5010
Chemical Information
Molecular Formula C25H45N5O13
CAS Registry Number 147245-92-9
SMILES CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O )O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual field defect06.02.07.003; 17.17.01.001---
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Xanthoma14.08.04.010; 23.03.03.047---
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.008---
Brain oedema12.01.10.010; 17.07.02.003--
Lhermitte's sign17.02.06.014---
Deep vein thrombosis24.01.02.003---
Injection site discolouration08.02.03.038; 12.07.03.038; 23.03.03.046---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Lymphatic disorder01.09.01.003---
Musculoskeletal stiffness15.03.05.027---
Musculoskeletal discomfort15.03.04.001---
Injection site swelling08.02.03.017; 12.07.03.018---
Affect lability19.04.01.001---
Haemorrhage24.07.01.002---
Rectal tenesmus07.03.03.001; 15.05.03.011---
Paraesthesia oral07.05.05.035; 17.02.06.008---
Major depression19.15.01.003---
Lung neoplasm malignant16.19.02.001; 22.08.01.001---
Nuchal rigidity15.05.04.005; 17.05.02.006---
Vasodilation procedure25.03.01.001---
Disturbance in sexual arousal19.08.04.003---
Angiopathy24.03.02.007---
Bacterial infection11.02.01.005---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages